ROIVANT SCIENCES LTD. Operating Expenses
ROIVANT SCIENCES LTD. (ROIV) reported Operating Expenses of $367.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- ROIVANT SCIENCES LTD. operating expenses for the quarter ending 2026-06-30 was $367.83M, a 28.12% increase year-over-year.
- ROIVANT SCIENCES LTD. operating expenses for the quarter ending 2026-03-31 was $357.51M, a 22.21% increase year-over-year.
- ROIVANT SCIENCES LTD. operating expenses for the quarter ending 2025-12-31 was $341.15M, a 20.38% increase year-over-year.
- ROIVANT SCIENCES LTD. operating expenses for the quarter ending 2025-09-30 was $307.80M, a 11.09% decline year-over-year.
- ROIVANT SCIENCES LTD. operating expenses for fiscal 2026 was $1.29B, a 13.20% increase from fiscal 2025.
- ROIVANT SCIENCES LTD. operating expenses for fiscal 2025 was $1.14B, a 29.26% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. operating expenses for fiscal 2024 was $884.09M, a 5.78% decline from fiscal 2023.
- ROIVANT SCIENCES LTD. operating expenses for fiscal 2023 was $938.29M, a 33.31% decline from fiscal 2022.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $367.83M 10-Q · filed 2026-08-06 | $725.34M derived: sum of 2 quarters · filed 2026-08-06 | $1.07B derived: sum of 3 quarters · filed 2026-08-06 | $1.37B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $357.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $698.67M derived: sum of 2 quarters · filed 2026-05-20 | $1.01B derived: sum of 3 quarters · filed 2026-05-20 | $1.29B 10-K · filed 2026-05-20 | ||||
| 2025-12-31 | $341.15M 10-Q · filed 2026-02-06 | $648.96M derived: sum of 2 quarters · filed 2026-02-06 | $936.05M 10-Q · filed 2026-02-06 | $1.23B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-09-30 | $307.80M 10-Q · filed 2025-11-10 | $594.90M 10-Q · filed 2025-11-10 | $887.43M derived: sum of 3 quarters · filed 2026-08-06 | $1.17B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $287.09M 10-Q · filed 2026-08-06 | $579.63M derived: sum of 2 quarters · filed 2026-08-06 | $863.03M derived: sum of 3 quarters · filed 2026-08-06 | $1.21B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $292.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $575.93M derived: sum of 2 quarters · filed 2026-05-20 | $922.12M derived: sum of 3 quarters · filed 2026-05-20 | $1.14B 10-K · filed 2026-05-20 | ||||
| 2024-12-31 | $283.40M 10-Q · filed 2026-02-06 | $629.59M derived: sum of 2 quarters · filed 2026-02-06 | $850.20M 10-Q · filed 2026-02-06 | $1.07B derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-09-30 | $346.19M 10-Q · filed 2025-11-10 | $566.80M 10-Q · filed 2025-11-10 | $782.65M derived: sum of 3 quarters · filed 2026-05-20 | $1.02B derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-06-30 | $220.61M 10-Q · filed 2025-08-11 | $285.70M 10-Q · filed 2024-08-09 | $436.47M derived: sum of 2 quarters · filed 2026-05-20 | $672.98M derived: sum of 3 quarters · filed 2026-05-20 | $890.52M derived: sum of 4 quarters · filed 2026-05-20 | |||
| 2024-03-31 | $215.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $452.37M derived: sum of 2 quarters · filed 2026-05-20 | $669.91M derived: sum of 3 quarters · filed 2026-05-20 | $884.09M 10-K · filed 2026-05-20 | $1.23B 10-K · filed 2024-05-30 | |||
| 2023-12-31 | $236.52M 10-Q · filed 2025-02-10 | $324.67M 10-Q · filed 2024-02-13 | $454.06M derived: sum of 2 quarters · filed 2025-02-10 | $668.24M 10-Q · filed 2025-02-10 | $936.26M 10-Q · filed 2024-02-13 | $715.33M derived: sum of 4 quarters · filed 2025-05-29 | ||
| 2023-09-30 | $217.54M 10-Q · filed 2024-11-12 | $313.56M 10-Q · filed 2023-11-13 | $431.72M 10-Q · filed 2024-11-12 | $611.59M 10-Q · filed 2023-11-13 | $478.81M derived: sum of 3 quarters · filed 2025-05-29 | $873.94M derived: sum of 4 quarters · filed 2025-05-29 | ||
| 2023-06-30 | $298.04M 10-Q · filed 2024-08-09 | $261.27M derived: sum of 2 quarters · filed 2025-05-29 | $656.40M derived: sum of 3 quarters · filed 2025-05-29 | $949.70M derived: sum of 4 quarters · filed 2025-05-29 | ||||
| 2023-03-31 | -$36.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | $358.37M derived: sum of 2 quarters · filed 2025-05-29 | $651.66M derived: sum of 3 quarters · filed 2025-05-29 | $938.29M 10-K · filed 2025-05-29 | $1.24B 10-K · filed 2023-06-28 | |||
| 2022-12-31 | $395.13M 10-Q · filed 2024-02-13 | $688.43M derived: sum of 2 quarters · filed 2024-02-13 | $975.06M 10-Q · filed 2024-02-13 | $1.25B derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-09-30 | $293.30M 10-Q · filed 2023-11-13 | $579.93M 10-Q · filed 2023-11-13 | $855.95M derived: sum of 3 quarters · filed 2023-11-13 | $1.13B derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $286.63M 10-Q · filed 2023-08-14 | $562.65M derived: sum of 2 quarters · filed 2023-08-14 | $833.02M derived: sum of 3 quarters · filed 2023-08-14 | $1.53B derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $276.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | $546.39M derived: sum of 2 quarters · filed 2023-06-28 | $1.24B derived: sum of 3 quarters · filed 2023-06-28 | $1.41B 10-K · filed 2023-06-28 | ||||
| 2021-12-31 | $270.36M 10-Q · filed 2023-02-13 | $968.78M derived: sum of 2 quarters · filed 2023-02-13 | $1.13B 10-Q · filed 2023-02-13 | $1.69B derived: sum of 4 quarters · filed 2023-02-13 | ||||
| 2021-09-30 | $698.42M 10-Q · filed 2022-11-14 | $860.54M 10-Q · filed 2022-11-14 | $1.42B derived: sum of 3 quarters · filed 2022-11-14 | $1.68B derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $162.12M 10-Q · filed 2022-08-15 | $718.10M derived: sum of 2 quarters · filed 2022-08-15 | $982.92M derived: sum of 3 quarters · filed 2022-08-15 | $1.14B derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $555.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-28 | $820.80M derived: sum of 2 quarters · filed 2022-06-28 | $978.66M derived: sum of 3 quarters · filed 2022-06-28 | $1.09B 10-K · filed 2022-06-28 | ||||
| 2020-12-31 | $264.82M 10-Q · filed 2022-02-14 | $422.68M derived: sum of 2 quarters · filed 2022-02-14 | $538.71M 10-Q · filed 2022-02-14 | |||||
| 2020-09-30 | $157.86M 10-Q · filed 2021-11-15 | $273.89M 10-Q · filed 2021-11-15 | ||||||
| 2020-06-30 | $116.03M 10-Q · filed 2021-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |